Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement

Background : Olmesartan medoxomil (OLM), an anti-hypertensive agent administered orally has absolute bioavailability of only 26% due to the poor aqueous solubility (<7.75 μg/ml). The present investigation aimed at enhancing the oral bioavailability of OLM by improving its solubility and dissoluti...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Hetal Paresh Thakkar (Автор), Bindesh Vishnubhai Patel (Автор), Sneha Piyush Thakkar (Автор)
Формат:
Опубликовано: Wolters Kluwer Medknow Publications, 2011-01-01T00:00:00Z.
Предметы:
Online-ссылка:Connect to this object online.
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_0e44b32b03284414919b855c7c45d0d0
042 |a dc 
100 1 0 |a Hetal Paresh Thakkar  |e author 
700 1 0 |a Bindesh Vishnubhai Patel  |e author 
700 1 0 |a Sneha Piyush Thakkar  |e author 
245 0 0 |a Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement 
260 |b Wolters Kluwer Medknow Publications,   |c 2011-01-01T00:00:00Z. 
500 |a 0975-7406 
500 |a 0976-4879 
500 |a 10.4103/0975-7406.84459 
520 |a Background : Olmesartan medoxomil (OLM), an anti-hypertensive agent administered orally has absolute bioavailability of only 26% due to the poor aqueous solubility (<7.75 μg/ml). The present investigation aimed at enhancing the oral bioavailability of OLM by improving its solubility and dissolution rate by preparing nanosuspensions. Materials and methods : The nanosuspensions of OLM were prepared using media milling technique followed by its lyophilization using mannitol as a cryoprotectant. Various formulation as well as process parameters were optimized in order to achieve desirable size and saturation solubility. Characterization of the prepared nanosuspension was done with respect to particle size, zeta potential, saturation solubility, dissolution rate, morphology study (TEM), in-vitro and exvivo drug diffusion study. Evaluation of the crystalline state before and after particle size reduction was done by differential scanning calorimetry (DSC) and powder X-ray diffraction (PXRD). Results : The results indicated that the initial crystalline state is preserved following particle size reduction and that the saturation solubility, dissolution velocity and diffusion rate of the drug from the nanosuspension is significantly higher than that of the plain drug suspension as well as from the marketed tablet formulation. Conclusion : Nanosuspension seems to be a promising approach for bioavailability enhancement because of the simple method of its preparation and its universal applicability. 
546 |a EN 
690 |a Bioavailability 
690 |a dissolution 
690 |a nanosuspension 
690 |a solubility 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
690 |a Analytical chemistry 
690 |a QD71-142 
655 7 |a article  |2 local 
786 0 |n Journal of Pharmacy and Bioallied Sciences, Vol 3, Iss 3, Pp 426-434 (2011) 
787 0 |n http://www.jpbsonline.org/article.asp?issn=0975-7406;year=2011;volume=3;issue=3;spage=426;epage=434;aulast=Thakkar 
787 0 |n https://doaj.org/toc/0975-7406 
787 0 |n https://doaj.org/toc/0976-4879 
856 4 1 |u https://doaj.org/article/0e44b32b03284414919b855c7c45d0d0  |z Connect to this object online.